Provided by Tiger Trade Technology Pte. Ltd.

Atossa Genetics

0.7311
+0.02693.82%
Post-market: 0.7165-0.0146-2.00%19:55 EST
Volume:945.80K
Turnover:678.90K
Market Cap:94.44M
PE:-3.11
High:0.7401
Open:0.7100
Low:0.7015
Close:0.7042
52wk High:1.29
52wk Low:0.5526
Shares:129.17M
Float Shares:129.10M
Volume Ratio:0.78
T/O Rate:0.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2348
EPS(LYR):-0.2026
ROE:-48.89%
ROA:-29.87%
PB:1.90
PE(LYR):-3.61

Loading ...

Atossa Therapeutics Reports Promising (Z)-Endoxifen Trial Results for Breast Cancer Treatment and Risk Reduction

Reuters
·
Dec 15

Atossa Therapeutics Inc. Announces Date for Upcoming Special Meeting of Stockholders

Reuters
·
Dec 13

Why Are Shares Of Atossa Therapeutics Up Today?

Benzinga_recent_news
·
Dec 12

FDA Grants Rare Pediatric Disease Designation to Atossa Therapeutics' (Z)-Endoxifen for Duchenne Muscular Dystrophy

Reuters
·
Dec 11

Atossa Therapeutics Granted U.S. Patent for Enteric Oral (Z)-Endoxifen Formulations and Treatment Methods

Reuters
·
Dec 09

Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen

THOMSON REUTERS
·
Dec 09

Atossa Therapeutics and Insilico Medicine Identify (Z)-Endoxifen as Potential Glioblastoma Treatment in AI-Driven Study

Reuters
·
Dec 02

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 17

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 14

Atossa Therapeutics Q3 net loss widens as operating costs rise

Reuters
·
Nov 12

Atossa Therapeutics Secures Israeli Patent for (Z)-Endoxifen, Strengthening Global IP Portfolio

Reuters
·
Nov 12

Atossa Therapeutics Q3 Pretax Profit USD -8.692 Million

THOMSON REUTERS
·
Nov 12

Atossa Therapeutics Q3 Operating Expenses USD 9.251 Million

THOMSON REUTERS
·
Nov 12

Top News Today/Canada: Barrick's Interim CEO Gets to Work

Dow Jones
·
Nov 11

Atossa Therapeutics Inc expected to post a loss of 7 cents a share - Earnings Preview

Reuters
·
Nov 07

Atossa Therapeutics Advances RECAST Trial Testing (Z)-Endoxifen for DCIS

Reuters
·
Oct 21

Health Rounds: Scientists find way to make breast cancer drug work better for younger women

Reuters
·
Oct 17

Atossa Therapeutics appoints Mark Daniel as CFO

TIPRANKS
·
Oct 14

Atossa Appoints Mark Daniel, Cpa, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness

THOMSON REUTERS
·
Oct 14

BRIEF-Atossa Therapeutics - Appoints Mark Daniel As CFO - SEC Filing

Reuters
·
Oct 14